Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Technical Presentation (November 2019)
18 slides from Corvus Pharmaceuticals's technical presentation, November 2019
Slide 1: SITC Annual Meeting, National Harbor, Maryland
vrecomenton center NOV. 6-10 NATIONAL HARBOR, MARYLAND € sitc Society for Immunotherapy of Cancer
Slide 2: Immunobiology and Clinical Activity of CPI-006, an Anti-CD73 Antibody
Immunobiology and Clinical Activity of CPI-006, an Anti-CD73 Antibody with Immunomodulating Properties in a Phase 1/1b Trial in Advanced Cancers Luke JJ, Merchan J, Harshman LC, Marron T, Powderly J, Barve M, LoRusso P, Johnson M, Hotson A, Gittelman R, Munneke B, Buggy J, Willingham S, Piccione E,
Slide 3: Disclosures
Disclosures Jason J. Luke: University of Pittsburgh Medical Center, Pittsburgh The following relationships exist related to this presentation: • Data and Safety Monitoring Board: TTC Oncology • Scientific Advisory Board: 7 Hills, Actym, Alphamab Oncology, Mavu, Pyxis, Springbank, Tempest • Consultan
Slide 4: Background
Background CPI-006 is an Anti-CD73 with Adenosine Independent Immunomodulatory Properties • CD73 is an ectoenzyme present on many tissues including subsets of T and B cells Adenosine – Converts AMP to adenosine AMP – Functions in lymphocyte adhesion, migration and activation1 Ciforadenant CD73 • CPI
Slide 5: CPI-006 is an Anti-CD73 with Unique Properties
CPI-006 is an Anti-CD73 with Unique Properties CPI-006 induces B cell differentiation: isotype switching and immunoglobulin secretion in vitro Isotype Control CPI-006 • CPI-006 activates B cells, resulting in morphological and CPI-006 surface marker changes consistent with B cell Day 7 differentiati
Slide 6: CPI-006-001 Clinical Trial Design
CPI-006-001 Clinical Trial Design Design Dose Escalation • Phase 1/1b dose escalation/dose expansion in disease specific cohorts CPI-006 CPI-006 + CPI-006 + CPI-006 + • CPI-006 every 3 weeks; fixed dose of ciforadenant Ciforadenant Pembrolizumab Ciforadenant + 24 mg/kg 24 mg/kg Pembrolizumab Eligibi
Slide 7: Patient Characteristics
Patient Characteristics Total Patients N=40 CPI-006 (N = 24) CPI-006 + Ciforadenant (N=16) Age (yrs), median (range) 62 (46, 78) 67 (36, 86) Gender, male N (%) 18 (75) 12 (75) No. of prior therapies, median (range) 4 (1, 6) 4 (2, 7) Histologies N N Renal Cell Cancer 2 4 Non-small cell lung cancer 2
Slide 8: Adverse Events
Adverse Events Adverse Events N (%) CPI-006 Monotherapy (N=24) CPI-006 + Ciforadenant (N= 16) All Grades Grade 3 or 4 All Grades Grade 3 or 4 Patients with any TEAE 18 ( 75.0) 4 ( 16.7) 12 ( 75.0) 2 ( 12.5) Anemia 1 ( 4.2) 1 ( 4.2) 2 ( 12.5) 1 ( 6.3) Lymphopenia 2 ( 8.3) 1 ( 4.2) 0 ( 0.0) 0 ( 0.0) C
Slide 9: Pharmacokinetics and Receptor Occupancy
Pharmacokinetics and Receptor Occupancy Tissue Occupancy Serum Pharmacokinetics B cell Target Occupancy ontrough 2b B Cells Peripheral (18 mg/kg CPI-006) at end of cycle CD73 with non-cross blocking antibody (total CD73) 1 mg/kg 6 mg/kg 18 mg/kg 150 3 mg/kg 12 mg/kg 24 mg/kg Serum Concentration(μg/m
Slide 10: Treatment Induces Rapid Changes in Blood B and T Cells
Treatment Induces Rapid Changes in Blood B and T Cells p < 0.0001 • Changes in B cells (but not T cells) appear to be CD73 expression dependent • B cell numbers partially return by 21 days; T cells fully return 10
Slide 11: Increase in Memory B Cells in Returning Lymphocytes
Increase in Memory B Cells in Returning Lymphocytes Peripheral Blood Gated on CD19+ and CD20+ B Cells Increased Memory B Cells at Day 21 Pre-treatment 30 min Day 21 Mem Cell FC (Reduced B cells) (Returning B cells: 6 p = n.s. p < 0.01 Memory Phenotype) 4 IgD 2 0 CD27 r 21 5h ay 0. • At 0.5 hours no
Slide 12: Significant Expansion of New B and T cell Clones
Significant Expansion of New B and T cell Clones Differential Abundance Plots of B cell Clonal Expansion Number of Number of New B cell clones on treatment present at high frequencies (up to 1:100) Cohort Patients with B Patients with T 10-2 10-2 Cell Expansion Cell Expansion RCC Patient 1 RCC Patie
Slide 13: Response Assessments
Response Assessments • Response assessments in patients receiving ≥ 6 mg/kg dose
Slide 14: Tumor Reduction in a Prostate Cancer Patient
Tumor Reduction in a Prostate Cancer Patient CPI-006 monotherapy Pre-treatment Post cycle 2 • 72 year old man with widely metastatic prostate cancer; • Decrease in target lesion in patient receiving 6 mg/kg previous therapies include leuprolide/bicalutamide, monotherapy, treatment ongoing through 19
Slide 15: Responding Pulmonary Metastases in RCC Patient
Responding Pulmonary Metastases in RCC Patient CPI-006 6 mg/kg plus ciforadenant combination Pre-treat Pre-treat • 36 year old male presented in 2015 with renal mass and bone metastases • Failed TKI, nivo and nivo/ipi with increase pulmonary mets • Regression of multiple biopsy proven pulmonary meta
Slide 16: Model for CPI-006 Effects on Cells
Model for CPI-006 Effects on Cells Blood Memory Lymph node B cell IgD- CD19+ CD20+ CD27+ CD73+ Plasmablast Naïve CPI-006 Activated B cell B cell IgM,G secreted IgD- IgD+ CD19+ CD19+ CD19+ CD20+ CD25+ CD20- CD20+ CD27- CD69+ CD27+ CD73+ CD83+ CD38+ HLA-DR↑ CD73+ HLA-DR- CD73-
Slide 17: Conclusions
Conclusions • CPI-006 has novel immunomodulatory activities: • Induces differentiation of B cells, class switching, secretion of immunoglobulin (in vitro), and generation of memory B cells • Increases expression of CD69 and other markers consistent with increased antigen presentation by APCs • The o
Slide 18: Acknowledgements
Acknowledgements • The patients and their families • Participating Centers and Investigators: Dana Farber Cancer Institute, Medical College of Wisconsin, Monash Health, Mount Sinai Icahn School of Medicine, University of California San Francisco Medical Center, University of Chicago, University of M
Corvus Pharmaceuticals — Technical Presentation (November 2019) on 6ix